Incyte Corp (INCY)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$50.00
Buy
$64.44
$-0.04 (-0.07%)
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.
Prices updated at 14 May 2025, 10:18 BST
| Prices minimum 15 mins delay
|
Prices in USD
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Biotechnology
Chairman
Mr. Herve Hoppenot
CEO
Mr. Herve Hoppenot
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
2,617
Head office
1801 Augustine Cut-Off
Wilmington
United States
19803
Key personnel
| Owner name | Salary | Bonus | All other compensation | Total compensation | Restricted stock award |
|---|---|---|---|---|---|
Mr. Barry P. Flannelly, Pharm.D. Executive Vice President and General Manager, North America | 0.62m | - | - | 4.34m | - |
Mr. Jean-Jacques Bienaime Independent Director | 0.09m | - | - | 0.52m | - |
Mr. Julian C. Baker Lead Independent Director | - | - | - | 0.55m | - |
Ms. Paula J. Swain Executive Vice President, Human Resources | - | - | - | - | - |
Mr. Paul J. Clancy, M.B.A. Independent Director | - | - | - | 0.52m | - |
Dr. Jacqualyn A. Fouse, PhD Independent Director | 0.08m | - | - | 0.51m | - |
Dr. Otis W. Brawley,M.D. Independent Director | 0.07m | - | - | 0.49m | - |
Dr. Pablo J. Cagnoni, M.D. President and Head of Research and Development | 0.93m | - | - | 7.90m | - |
Ms. Christiana Stamoulis, M.B.A. Executive Vice President and Chief Financial Officer | 0.71m | - | - | 5.40m | - |
Dr. Edmund P. Harrigan, M.D. Independent Director | - | - | - | 0.52m | - |
Mr. Herve Hoppenot Chairman of the Board, President and Chief Executive Officer | 1.34m | - | - | 17.46m | - |
Dr. Katherine A. High, M.D. Independent Director | 0.07m | - | - | 0.49m | - |
Mr. Vijay K. Iyengar Executive Vice President, Global Strategy and Corporate Development | - | - | - | - | - |
Dr. Steven H. Stein, M.D. Executive Vice President and Chief Medical Officer | 0.81m | - | - | 5.98m | - |
Dr. Susanne Schaffert, PhD Independent Director | 0.08m | - | - | 0.50m | - |
Mr. Michael James Morrissey Executive Vice President and Head of Global Technical Operations | - | - | - | - | - |
Mr. Thomas Tray Vice President and Chief Accounting Officer | - | - | - | - | - |
Ms. Sheila A Denton Executive Vice President, General Counsel and Corporate Secretary | - | - | - | - | - |
Mr. Matteo Trotta Executive Vice President and General Manager, Dermatology US | - | - | - | - | - |
Mr. Lee Heeson Executive Vice President, Incyte International | - | - | - | - | - |
Mr. Mohamed Khairie Issa Executive Vice President and Head of US Oncology | - | - | - | - | - |
Top 5 shareholders
| Owner name | No. of shares | Share as % of port. | Last change | Portfolio % change | Date of portfolio | % Total assets |
|---|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 36,194,665 | - | -113919 | -0.313752 | 30 Apr 2025 | 18.79 |
| Baker Bros Advisors LP | 30,739,466 | 22.67988 | 446 | 0.001451 | 30 Apr 2025 | 15.88 |
| Vanguard Group Inc | 19,997,823 | 0.02189 | 417346 | 2.131439 | 30 Apr 2025 | 10.33 |
| BlackRock, Inc. | 17,077,446 | - | 17077446 | - | 30 Apr 2025 | 8.86 |
| BlackRock Inc | 16,510,467 | 0.02308 | -567293 | -3.321823 | 30 Apr 2025 | 8.53 |
Director dealings
| Date | Action | Name | Price | Value | No. of shares | Holding (%) | Additional info |
|---|---|---|---|---|---|---|---|
| 31 Dec 2024 | - | Mr. Paul J. Clancy | 69.07 | 22,862 | 19,713 | - | - |
| 31 Dec 2024 | - | Dr. Edmund P. Harrigan, M.D. | 69.07 | 23,415 | 17,071 | - | - |
| 16 Dec 2024 | - | Mr. Thomas Tray | 69.31 | 45,052 | 23,312 | - | - |
| 13 Dec 2024 | - | Mr. Thomas Tray | 70.64 | 45,916 | 23,962 | - | - |
| 09 Dec 2024 | - | Ms. Paula J. Swain | 72.11 | 62,952 | 85,203 | - | - |
| 09 Dec 2024 | - | Mr. Barry P. Flannelly, Pharm.D. | 72.11 | 108,886 | 56,532 | - | - |
| 29 Nov 2024 | - | Mr. Vijay K. Iyengar | 75.37 | 428,328 | 30,658 | - | - |
| 29 Nov 2024 | - | Mr. Vijay K. Iyengar | 75.60 | 27,216 | 36,341 | - | - |
| 06 Nov 2024 | - | Mr. Barry P. Flannelly, Pharm.D. | 68.62 | 154,807 | 61,722 | - | - |
| 06 Nov 2024 | - | Mr. Barry P. Flannelly, Pharm.D. | - | - | - | - | - |
| 06 Nov 2024 | - | Mr. Barry P. Flannelly, Pharm.D. | - | - | - | - | - |
| 06 Nov 2024 | - | Mr. Barry P. Flannelly, Pharm.D. | 78.21 | 176,442 | 58,042 | - | - |
| 06 Nov 2024 | - | Mr. Barry P. Flannelly, Pharm.D. | 82.00 | 116,768 | 60,298 | - | - |
| 06 Nov 2024 | - | Mr. Barry P. Flannelly, Pharm.D. | 72.27 | 102,912 | 59,466 | - | - |
| 02 Oct 2024 | - | Ms. Sheila A Denton | 67.63 | 144,458 | 30,343 | - | - |
| 01 Oct 2024 | - | Mr. Lee Heeson | - | - | 26,447 | - | - |
| 30 Sep 2024 | - | Mr. Paul J. Clancy | 66.10 | 24,325 | 19,382 | - | - |
| 30 Sep 2024 | - | Dr. Edmund P. Harrigan, M.D. | 66.10 | 24,986 | 16,732 | - | - |
| 12 Sep 2024 | - | Mr. Jonathan Elliott Dickinson | 62.37 | 457,359 | 36,390 | - | - |
| 12 Sep 2024 | - | Mr. Jonathan Elliott Dickinson | 62.30 | 69,589 | 43,723 | - | - |
Please note that past performance is not a reliable indicator of future returns.
